Why Is RECURSION PHARMACEUT A (RXRX) Stock Up Today?
By the Top Tier Newswire AI Desk · October 15, 2026 at 10:59 AM ET · reviewed against 10 wire stories
RECURSION PHARMACEUT A (RXRX) is up +7.37% in the latest session. Our newswire has captured 10 stories on RXRX across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 43/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Recursion Pharmaceuticals (RXRX) shares rose 7.37% to $4.02 on Wednesday. The primary driver was the company’s announcement that Sanofi exercised its option to develop a first-in-class immunology candidate from their collaboration, triggering a $10 million milestone payment. This positive catalyst coincided with the pricing of a $200 million equity offering.
What Happened
Recursion Pharmaceuticals disclosed that Sanofi selected its first AI drug candidate under their research agreement. This decision triggers a $10 million milestone payment and opens the door for potential Phase 1 trials in 2027. Simultaneously, the company priced an offering of 61.54 million shares of Class A common stock at $3.25 per share. The equity raise is intended to strengthen the balance sheet and advance the pipeline. A Form 8-K filed on October 15, 2026, detailed the entry into the material definitive agreement and the financial results. The company also reported early data from the REC-1245 trial and provided an update on REC-4881 data.
What The Data Shows
The stock opened at $3.65, a 2.4% gap down from the prior close of $3.74. It hit a session low of $3.08 at 8:20 AM ET before climbing to a session high of $4.03 at 10:55 AM ET. Volume reached 19.6 million shares, which is 0.9 times the three-month daily average. The company has a market capitalization of $2.1 billion and is unprofitable, with trailing twelve-month earnings per share of negative $1.02. Revenue declined 15.1% over the same period. The stock printed a fresh 52-week low on October 15, 2026, within a 52-week range of $2.77 to $7.18. Over the last eight sessions, the stock fell 21.8% from $4.78 to $3.74. Recent insider activity includes five sales totaling $644,000 in the last 90 days, with no buys. Directors Blake Borgeson and Robert Hershberg sold shares on October 6, 2026, while CEO Najat Khan sold on September 8, 2026.
What To Watch
Investors will monitor the execution of the $200 million equity offering and the progress of the Sanofi collaboration toward Phase 1 trials in 2027.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RXRX · today's session (5-min) · +12.70% vs prior close · updated 3:36 PM ETAI sentiment, last 36h · averaged over 10 stories · 43/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoTipRanksBEARISH 28General
Recursion Pharmaceuticals prices offering and advances pipeline
The latest announcement is out from Recursion Pharmaceuticals ( ($RXRX) ). On Oct. 15, 2026, Recursion Pharmaceuticals moved to strengthen its balance sheet and pip...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a research deal between the two. Read more here.
7h agoThe FlyBULLISH 58Product/PR
Recursion Pharmaceuticals reports early data from REC-1245 trial
7h agoThe FlyBULLISH 56Product/PR
Recursion Pharmaceuticals provides update on REC-4881 data
7h agoThe FlyBULLISH 64Product/PR
Recursion announces Sanofi option for development candidate
7h agoSEC 8-KNEUTRAL 50General
RECURSION PHARMACEUTICALS, INC. (RXRX) files 8-K
Filed: 2026-10-15 AccNo: 0001601830-26-000128 Size: 8 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
7h agoBusiness InsiderBULLISH 64Product/PR
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“
7h agoThe FlyBEARISH 22General
Recursion Pharmaceuticals prices 61.54M shares of Class A common stock at $3.25
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →